Targeted urine proteomics in lupus nephritis – a meta-analysis

References

• Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835.
   PubMed Web of Science ®Google Scholar
• Giannico G, Fogo AB. Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013;8(1):138–145.
   PubMed Web of Science ®Google Scholar
• Zhang T, Li H, Vanarsa K, et al. Association of urine sCD163 with proliferative lupus nephritis, fibrinoid necrosis, cellular crescents and intrarenal M2 macrophages. Front Immunol. 2020;11:671.
   PubMed Web of Science ®Google Scholar
• Parodis I, Gokaraju S, Zickert A, et al. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. Rheumatology (Oxford). 2020;59(9):2237–2249.
   PubMed Web of Science ®Google Scholar
• Soliman S, Mohan C. Lupus nephritis biomarkers. Clin Immunol. 2017;185:10–20. .
   PubMed Web of Science ®Google Scholar
• Mok CC, Soliman S, Ho LY, et al. Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis. Arthritis Res Ther. 2018;20(1):6.
   PubMed Web of Science ®Google Scholar
• Qin L, Stanley S, Ding H, et al. Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis. Arthritis Res Ther. 2019;21(1):176.
   PubMed Web of Science ®Google Scholar
• Nicolaou O, Kousios A, Hadjisavvas A, et al. Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review. J Cell Mol Med. 2017;21(5):993–1012.
   PubMed Web of Science ®Google Scholar
• Hoyer KJR, Dittrich S, Bartram MP, et al. Quantification of molecular heterogeneity in kidney tissue by targeted proteomics. J Proteomics. 2019;193:85–92.
   PubMed Web of Science ®Google Scholar
• Konvalinka A, Scholey JW, Diamandis EP. Searching for new biomarkers of renal diseases through proteomics. Clin Chem. 2012;58(2):353–365.
   PubMed Web of Science ®Google Scholar
• Altelaar AF, Munoz J, Heck AJ. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet. 2013;14(1):35–48.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Klein JB. Proteomics and autoimmune kidney disease. Clin Immunol. 2015;161(1):23–30.
   PubMed Web of Science ®Google Scholar
• Korte EA, Gaffney P, Powell DW, et al. Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus. Arthritis Res Ther. 2012;14(1):204.
   PubMed Web of Science ®Google Scholar
• Caster DJ, Hobeika L, Klein JB, et al. Changing the concepts of immune-mediated glomerular diseases through proteomics. Proteomics Clin Appl. 2015;9(11–12):967–971.
   PubMed Web of Science ®Google Scholar
• L’Imperio V, Smith A, Chinello C, et al. Proteomics and glomerulonephritis: a complementary approach in renal pathology for the identification of chronic kidney disease related markers. Proteomics Clin Appl. 2016;10(4):371–383.
   PubMed Web of Science ®Google Scholar
• Kalantari S, Jafari A, Moradpoor R, et al. Human urine proteomics: analytical techniques and clinical applications in renal diseases. Int J Proteomics. 2015;2015:782798.
   PubMedGoogle Scholar
• Paul P, Antonydhason V, Gopal J, et al. Bioinformatics for renal and urinary proteomics: call for aggrandization. Int J Mol Sci. 2020;21(3):3.
   Web of Science ®Google Scholar
• Thomas S, Hao L, Ricke WA, et al. Biomarker discovery in mass spectrometry-based urinary proteomics. Proteomics Clin Appl. 2016;10(4):358–370.
   PubMed Web of Science ®Google Scholar
• Jiang S, Wang Y, Liu Z. The application of urinary proteomics for the detection of biomarkers of kidney diseases. Adv Exp Med Biol. 2015;845:151–165.
   PubMed Web of Science ®Google Scholar
• Vanarsa K, Mohan C. Proteomics in rheumatology: the dawn of a new era. F1000 Med Rep. 2010;2:87.
   PubMedGoogle Scholar
• Kim MJ, Frankel AH, Tam FW. Urine proteomics and biomarkers in renal disease. Nephron Exp Nephrol. 2011;119(1):e1–7.
   PubMedGoogle Scholar
• Aggarwal A, Gupta R, Negi VS, et al. Urinary haptoglobin, alpha-1 anti-chymotrypsin and retinol binding protein identified by proteomics as potential biomarkers for lupus nephritis. Clin Exp Immunol. 2017;188(2):254–262.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jin M, Wu H, et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 2008;74(6):799–807.
   PubMed Web of Science ®Google Scholar
• Stanley S, Mok CC, Vanarsa K, et al. Identification of low-abundance urinary biomarkers in lupus nephritis using electrochemiluminescence immunoassays. Arthritis Rheumatol. 2019;71(5):744–755.
   PubMed Web of Science ®Google Scholar
• Stanley S, Vanarsa K, Soliman S, et al. Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. Nat Commun. 2020;11(1): 2197.
   PubMed Web of Science ®Google Scholar
• Vanarsa K, Soomro S, Zhang T, et al. Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. Ann Rheum Dis. 2020;79(10): 1349–1361.
   PubMed Web of Science ®Google Scholar
• Wu J, Chen YD, Gu W. Urinary proteomics as a novel tool for biomarker discovery in kidney diseases. J Zhejiang Univ Sci B. 2010;11(4):227–237.
   PubMed Web of Science ®Google Scholar
• Jakiela B, Kosałka J, Plutecka H, et al. Urinary cytokines and mRNA expression as biomarkers of disease activity in lupus nephritis. Lupus. 2018;27(8):1259–1270.
   PubMed Web of Science ®Google Scholar
• Fava A, Buyon J, Mohan C, et al., Integrated urine proteomics and renal single-cell genomics identify an IFN-gamma response gradient in lupus nephritis. JCI Insight. 2020;5(12): 12.
   Web of Science ®Google Scholar
• Der E, Suryawanshi H, Morozov P, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019;20(7): 915–927.
   PubMed Web of Science ®Google Scholar
• Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888–902 e21.
   PubMed Web of Science ®Google Scholar
• Butler A, Hoffman P, Smibert P, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411–420.
   PubMed Web of Science ®Google Scholar
• Perez de Lema G, Maier H, Nieto E, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001;12(7):1369–1382.
   PubMed Web of Science ®Google Scholar
• Kulkarni OAH. Chemokines in lupus nephritis. Front Biosci. 2008;13:3312–3320.
   PubMed Web of Science ®Google Scholar
• BH. R. The chemokine network in systemic lupus erythematous nephritis. Front Biosci. 2008;13(13):904–922.
   PubMed Web of Science ®Google Scholar
• Vielhauer V, Anders HJ, Schlöndorff D, et al. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin Nephrol. 2007;27(1):81–97.
   PubMed Web of Science ®Google Scholar
• Liao X, Pirapakaran T, Luo XM. Chemokines and chemokine receptors in the development of lupus nephritis. Mediators Inflammation. 2016;2016:6012715.
   PubMed Web of Science ®Google Scholar
• Puapatanakul P, Chansritrakul S, Susantitaphong P, et al. Interferon-inducible protein 10 and disease activity in systemic lupus erythematosus and lupus nephritis: a systematic review and meta-analysis. Int J Mol Sci. 2019;20(19):19.
   Web of Science ®Google Scholar
• Wu T, Xie C, Wang HW, et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol. 2007;179(10):7166–7175.
   PubMed Web of Science ®Google Scholar
• Sun MY, Wang SJ, Li XQ, et al. CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway. Front Pharmacol. 2019;10:224.
   PubMed Web of Science ®Google Scholar
• Hoste E, Bihorac A, Al-Khafaji A, et al. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med. 2020;46(5):943–953.
   PubMed Web of Science ®Google Scholar
• Vyshkina T, Sylvester A, Sadiq S, et al. CCL genes in multiple sclerosis and systemic lupus erythematosus. J Neuroimmunol. 2008;200(1–2):145–152.
   PubMed Web of Science ®Google Scholar
• Cappello P, Caorsi C, Bosticardo M, et al. CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. J Leukoc Biol. 2004;75(1):135–142.
   PubMed Web of Science ®Google Scholar
• Strasly M, Doronzo G, Cappello P, et al. CCL16 activates an angiogenic program in vascular endothelial cells. Blood. 2004;103(1):40–49.
   PubMed Web of Science ®Google Scholar
• Inaba A, Tuong ZK, Riding AM, et al. B lymphocyte-derived CCL7 augments neutrophil and monocyte recruitment, exacerbating acute kidney injury. J Immunol. 2020;205(5):1376–1384.
   PubMed Web of Science ®Google Scholar
• Gonzalez J, Mouttalib S, Delage C, et al. Dual effect of chemokine CCL7/MCP-3 in the development of renal tubulointerstitial fibrosis. Biochem Biophys Res Commun. 2013;438(2):257–263.
   PubMed Web of Science ®Google Scholar
• Chakravorty SJ, Howie AJ, Girdlestone J, et al. Potential role for monocyte chemotactic protein-4 (MCP-4) in monocyte/macrophage recruitment in acute renal inflammation. J Pathol. 2001;194(2):239–246.
   PubMed Web of Science ®Google Scholar
• Montero RM, Bhangal G, Pusey CD, et al. CCL18 synergises with high concentrations of glucose in stimulating fibronectin production in human renal tubuloepithelial cells. BMC Nephrol. 2016;17(1):139.
   PubMed Web of Science ®Google Scholar
• Brix SR, Stege G, Disteldorf E, et al. CC chemokine ligand 18 in ANCA-associated crescentic GN. J Am Soc Nephrol. 2015;26(9):2105–2117.
   PubMed Web of Science ®Google Scholar
• Mohan T, Deng L, Wang BZ. CCL28 chemokine: an anchoring point bridging innate and adaptive immunity. Int Immunopharmacol. 2017;51:165–170.
   PubMed Web of Science ®Google Scholar
• Noels H, Bernhagen J, Weber C, et al. Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med. 2009;19(3):76–86.
   PubMed Web of Science ®Google Scholar
• Lan HY, Yang N, Nikolic-Paterson DJ, et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int. 2000;57(2):499–509.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Slavin L, Hoi AY, et al. Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000277.
   PubMed Web of Science ®Google Scholar
• Tu Y, Guo R, Li J, et al. MiRNA regulation of MIF in SLE and attenuation of murine lupus nephritis with miR-654. Front Immunol. 2019;10:2229.
   PubMed Web of Science ®Google Scholar
• Otukesh H, Chalian M, Hoseini R, et al. Urine macrophage migration inhibitory factor in pediatric systemic lupus erythematosus. Clin Rheumatol. 2007;26(12):2105–2107.
   PubMed Web of Science ®Google Scholar
• Li JH, Tang Y, Lv J, et al. Macrophage migration inhibitory factor promotes renal injury induced by ischemic reperfusion. J Cell Mol Med. 2019;23(6):3867–3877.
   PubMed Web of Science ®Google Scholar
• Wang J, Li Y, Chen Y, et al. Urinary macrophage migration inhibitory factor as a noninvasive biomarker in pediatric Henoch-Schonlein purpura nephritis. J Clin Rheumatol. 2017;23(5):258–261.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Kanmatsuse K. Urinary levels of macrophage migration inhibitory factor in patients with IgA nephropathy. Nephron. 2002;92(2):309–315.
   PubMed Web of Science ®Google Scholar
• Brown FG, Nikolic-Paterson DJ, Hill PA, et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol. 2002;13(Suppl 1):S7–13.
   PubMed Web of Science ®Google Scholar
• Sakly N, Mirshahi P, Ducros E, et al. Angiogenic activity in sera of patients with systemic lupus erythematosus. Lupus. 2009;18(8):705–712.
   PubMed Web of Science ®Google Scholar
• Wu T, Du Y, Han J, et al. Urinary angiostatin–a novel putative marker of renal pathology chronicity in lupus nephritis. Mol Cell Proteomics. 2013;12(5):1170–1179.
   PubMed Web of Science ®Google Scholar
• Yang X, Cheng Y, Su G. A review of the multifunctionality of angiopoietin-like 4 in eye disease. Biosci Rep. 2018;38(5):5.
   Web of Science ®Google Scholar
• Y Oy I, Yasunaga K, Hamada K, et al. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. Cancer Res. 2003;63(20):6651–6657.
   PubMed Web of Science ®Google Scholar
• A T-M, Patel JV, Lip GY. Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost. 2006;4(9):1864–1874.
   PubMed Web of Science ®Google Scholar
• Kuwahara A, Jinnin M, Makino T, et al. Angiogenin expression in the sera and skin of patients with rheumatic diseases. Biosci Trends. 2012;6(5):229–233.
   PubMed Web of Science ®Google Scholar
• MS J, Weakley S, Yao Q, et al. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012;165(3):622–632.
   PubMed Web of Science ®Google Scholar
• Park HK, Kwak MK, Kim HJ, et al. Linking resistin, inflammation, and cardiometabolic diseases. Korean J Intern Med. 2017;32(2):239–247.
   PubMed Web of Science ®Google Scholar
• Acquarone E, Monacelli F, Borghi R, et al. Resistin: a reappraisal. Mech Ageing Dev. 2019;178:46–63.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Pawlak K, et al. Resistin, a new adipokine, is related to inflammation and renal function in kidney allograft recipients. Transplant Proc. 2006;38(10):3434–3436.
   PubMed Web of Science ®Google Scholar
• Bonito B, Silva AP, Rato F, et al. Resistin as a predictor of cardiovascular hospital admissions and renal deterioration in diabetic patients with chronic kidney disease. J Diabetes Complications. 2019;33(11):107422.
   PubMed Web of Science ®Google Scholar
• Tsai HC, Cheng S, Han CK, et al. Resistin enhances angiogenesis in osteosarcoma via the MAPK signaling pathway. Aging (Albany NY). 2019;11(21):9767–9777.
   PubMedGoogle Scholar
• TP Z, Li H, Li R, et al. Association of omentin-1, adiponectin, and resistin genetic polymorphisms with systemic lupus erythematosus in a Chinese population. Int Immunopharmacol. 2020;83:106343.
   PubMed Web of Science ®Google Scholar
• Hutcheson J, Ye Y, Han J, et al. Resistin as a potential marker of renal disease in lupus nephritis. Clin Exp Immunol. 2015;179(3):435–443.
   PubMed Web of Science ®Google Scholar
• Wang XD, Huang XF, Yan QR, et al. Aberrant activation of the WNT/beta-catenin signaling pathway in lupus nephritis. PLoS One. 2014;9(1):e84852.
   PubMed Web of Science ®Google Scholar
• Xue J, Yang J, Yang L, et al. Dickkopf-1 is a biomarker for systemic lupus erythematosus and active lupus nephritis. J Immunol Res. 2017;2017:6861575.
   PubMed Web of Science ®Google Scholar
• Rupanagudi KV, Kulkarni OP, Lichtnekert J, et al. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis. 2015;74(2):452–463.
   PubMed Web of Science ®Google Scholar
• Yao X, Cheng F, Yu W, et al. Cathepsin S regulates renal fibrosis in mouse models of mild and severe hydronephrosis. Mol Med Rep. 2019;20(1):141–150.
   PubMed Web of Science ®Google Scholar
• Thanei S, Theron M, Silva AP, et al. Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages. Biochem Pharmacol. 2017;146:151–164.
   PubMed Web of Science ®Google Scholar
• Zhang TP, Li HM, Leng RX, et al. Plasma levels of adipokines in systemic lupus erythematosus patients. Cytokine. 2016;86:15–20.
   PubMed Web of Science ®Google Scholar
• Wang M, Sampson ER, Jin H, et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther. 2013;15(1):R5.
   PubMed Web of Science ®Google Scholar
• Cabrera S, Maciel M, Hernandez-Barrientos D, et al. Delayed resolution of bleomycin-induced pulmonary fibrosis in absence of MMP13 (collagenase 3). Am J Physiol Lung Cell Mol Physiol. 2019;316(5):L961–L76.
   PubMed Web of Science ®Google Scholar
• QQ Z, Li T, Chen R, et al. Elevated serum levels of MMP-2, MMP-3, and MMP-13 in Chinese patients with systemic lupus erythematosus. Scand J Rheumatol. 2010;39(5):439–441.
   PubMed Web of Science ®Google Scholar
• Wang W, Knovich MA, Coffman LG, et al. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010;1800(8):760–769.
   PubMed Web of Science ®Google Scholar
• McCullough KBS, Bolisetty S. Ferritins in kidney disease. Semin Nephrol. 2020;40(2):160–172.
   PubMed Web of Science ®Google Scholar
• R T, Panda A, Das BK. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE. Lupus. 2015;24(1):82–89.
   PubMed Web of Science ®Google Scholar
• Wu T, Ding H, Han J, et al. Antibody-array-based proteomic screening of serum markers in systemic lupus erythematosus: a discovery study. J Proteome Res. 2016;15(7):2102–2114.
   PubMed Web of Science ®Google Scholar
• Qi L, Xu J, Yang C, et al. Urinary ferritin creatinine ratio, a potential biomarker for lupus nephritis activity. Clin Rheumatol. 2020;40(1):143–149.
   PubMed Web of Science ®Google Scholar
• Lorz C, Ortiz A, Justo P, et al. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol. 2000;11(7):1266–1277.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Kandane-Rathnayake R, Koelmeyer R, et al. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. Lupus Sci Med. 2020;7(1):1.
   Web of Science ®Google Scholar
• I B-A, Daza L, Avalos-Díaz E, et al. Glomerular expression of Fas ligand and Bax mRNA in lupus nephritis. Autoimmunity. 2001;34(4):283–289.
   PubMed Web of Science ®Google Scholar
• Jh Qq C, Guo Y, Zhang YQ, et al. Increased apoptosis and expression of FasL, Bax and caspase-3 in human lupus nephritis class II and IV. J Nephrol. 2012;25(2):255–261.
   PubMed Web of Science ®Google Scholar
• Tsukinoki T, Sugiyama H, Sunami R, et al. Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-kappaB-mediated expression in cultured human mesangial cells. Clin Exp Nephrol. 2004;8(3):196–205.
   PubMedGoogle Scholar
• Zhang D, Gava AL, Van Krieken R, et al. The caveolin-1 regulated protein follistatin protects against diabetic kidney disease. Kidney Int. 2019;96(5):1134–1149.
   PubMed Web of Science ®Google Scholar
• D’Ignazio L, Batie M, Rocha S. TNFSF14/LIGHT, a non-canonical NF-kappaB stimulus, induces the hif pathway. Cells. 2018;7(8):8.
   Web of Science ®Google Scholar
• Yang Y, Meng L, Wu S, et al. LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis. Int Immunopharmacol. 2020;89(Pt A):106999.
   PubMed Web of Science ®Google Scholar
• Harley RJ, Murdy JP, Wang Z, et al. Neuronal cell adhesion molecule (NrCAM) is expressed by sensory cells in the cochlea and is necessary for proper cochlear innervation and sensory domain patterning during development. Dev Dyn. 2018;247(7):934–950.
   PubMed Web of Science ®Google Scholar